Denali Therapeutics (DNLI) Return on Equity (2018 - 2024)
Historic Return on Equity for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to 0.12%.
- Denali Therapeutics' Return on Equity rose 2000.0% to 0.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.37% for FY2024, which is 2300.0% down from last year.
- Denali Therapeutics' Return on Equity amounted to 0.12% in Q3 2025, which was up 2000.0% from 0.21% recorded in Q2 2025.
- Denali Therapeutics' 5-year Return on Equity high stood at 0.05% for Q2 2021, and its period low was 0.37% during Q1 2023.
- Its 5-year average for Return on Equity is 0.2%, with a median of 0.27% in 2025.
- In the last 5 years, Denali Therapeutics' Return on Equity skyrocketed by 5100bps in 2021 and then crashed by -3900bps in 2022.
- Denali Therapeutics' Return on Equity (Quarter) stood at 0.29% in 2021, then fell by -20bps to 0.35% in 2022, then surged by 62bps to 0.14% in 2023, then tumbled by -146bps to 0.33% in 2024, then soared by 65bps to 0.12% in 2025.
- Its Return on Equity was 0.12% in Q3 2025, compared to 0.21% in Q2 2025 and 0.27% in Q1 2025.